Journal
MINI-REVIEWS IN MEDICINAL CHEMISTRY
Volume 11, Issue 9, Pages 746-752Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/138955711796355249
Keywords
Thyroid cancer; sunitinib; tyrosin-kinase inhibitor; metastatic disease
Categories
Ask authors/readers for more resources
Tyrosine kinase receptors have been shown to play an important role in epithelial thyroid tumor growth and angiogenesis. Thyroid cancers commonly present oncogene mutations involved in MAPK kinase pathway like BRAF and RET; they are also frequently dependent on VEGF stimuli. Preliminary clinical experiences suggest a promising role of sunitinib (a tyrosine kinase inhibitor) for the treatment of advanced thyroid cancers. This review deals with the available data on the effect of sunitinib in the treatment of metastatic, radioiodine refractory thyroid cancers. We also report our experience with the off-label use of sunitinib in such patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available